Zentalis appoints Julie Eastland CEO, succeeding Blackwell; plans registrational studies for azenosertib

Zentalis Pharmaceuticals, Inc.

Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.
Ingmar Bruns appointed Chief Medical Officer; Scott Myers appointed Board Chairperson.
Cam Gallagher resigned as President/Interim CFO; Vincent Vultaggio named interim principal financial officer.
Board approved amendment to 2022 Inducement Plan, increasing available shares by 5,500,000.
Company plans to host investor event in Jan 2025 with updated azenosertib data and regulatory update.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Julie Eastland

Chief Executive Officer, President and a Class I director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-11-13
Filed: November 13, 2024, 6:59 PM ET

On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).

Departed

Kimberly Blackwell

Chief Executive Officer and Director

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2024-11-13
Successor: Julie Eastland
Filed: November 13, 2024, 6:59 PM ET

Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Julie Eastland was appointed as Chief Executive Officer, President and a Class I director at Zentalis Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer, President and a Class I director

Exact text from the filing

On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kimberly Blackwell resigned as Chief Executive Officer and Director at Zentalis Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer and Director

Exact text from the filing

Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-24-000177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.